Risk evaluation of splenic hilar lymph node metastasis and survival analysis of patients with advanced gastric cancer

作     者：Guang-Cai Niu You-Long Zhu Xuan-Xuan Xiong Guang-Cai Niu;You-Long Zhu;Xuan-Xuan Xiong

作者机构：Department of Gastrointestinal SurgeryXuzhou Central HospitalXuzhouChina Department of GastroenterologyXuzhou Central HospitalXuzhouChina 

出 版 物：《Oncology and Translational Medicine》 (肿瘤学与转化医学（英文版）)

年 卷 期：2023年第9卷第5期

页      面：219-224页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the Department of Gastrointestinal Surgery Xuzhou Central Hospital Xuzhou China 

主　　题：Advanced gastric cancer(AGC) Complication No.10 lymphadenectomy Survival time 

摘      要：Background:There is no consensus regarding the influence of prophylactic no.10 lymph node(LN)dissection in patients with advanced gastric cancer(AGC).We aimed to evaluate whether patients with AGC could benefit from no.10 LN dissection and to explore the clinicopathological indicators of no.10 LN ***:We analyzed the data of 218 patients with AGC who underwent standard D2 lymphadenectomy(SD2;n=108)or modified D2 lymphadenectomy(MD2;n=110)between January 2017 and January *** addition,we examined factors influencing no.10 LN metastasis in the SD2 ***:Differentiation,tumor location,and no.4 positive LNs were significantly correlated with no.10 LN metastasis(P0.05).The median survival times were 72.23 and 68.56months for the SD2 andMD2 groups,respectively(P=0.635).Postoperative major morbidity and mortality rates were 37.96%and 3.70%in the SD2 group,and 23.64%and 1.82%in the MD2 group,***:Based on our findings,prophylactic no.10 lymphadenectomy may be recommended in patients with AGC who exhibit positive no.4 LN status,poor differentiation,and tumors located on the greater curvature.